This is a summary of the European public assessment report (EPAR) for Cholib. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Cholib. For practical information about using Cholib, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Cholib is indicated as adjunctive therapy to diet and exercise in high cardiovascular risk adult patients with mixed dyslipidaemia to reduce triglycerides and increase HDL C levels when LDL C levels are adequately controlled with the corresponding dose of simvastatin monotherapy.
Therapeutic Area (MeSH)
ATC Code
C10BA04
ATC Item
simvastatin and fenofibrate
Pharmacotherapeutic Group
Lipid modifying agents
Active Substance (Summary)
INN / Common Names
EMA Name
Cholib
Medicine Name
Cholib
Aliases
N/A